Psychometric properties of the Japanese version of the Kansas City Cardiomyopathy Questionnaire in Japanese patients with chronic heart failure

Watanabe-Fujinuma, Emi; Origasa, Hideki; Bamber, Luke; Roessig, Lothar; Toyoda, Tetsumi; Haga, Yuri; Gwaltney, Chad J.; Pieske, Burkert

doi:10.1186/s12955-020-01483-0

Cited by 3 publications

(4 citation statements)

References 37 publications

(60 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For instance, validated HF-specific instruments such as the Kansas City Cardiomyopathy Questionnaire in a patient's native language should be used when possible. 42,43 Deliberate site selection can play an important role in enriching enrollment of particular patient groups. 44 This may involve economic incentives to support centers in their enrollment efforts as well as engagement with investigators in other countries to target greater balance in sex, gender, race, and ethnicity in global trials.…”

Section: Research Study Design and Site Selectionmentioning

confidence: 99%

See 1 more Smart Citation

Improving Enrollment of Underrepresented Racial and Ethnic Populations in Heart Failure Trials

et al. 2022

View full text Add to dashboard Cite

ome racial and ethnic populations, particularly Black and Hispanic individuals, have a greater burden of heart failure (HF), are less likely to receive optimal disease-modifying therapies, and are more likely to die from HF. [1][2][3][4][5] Despite this excess risk, these same populations are often the least studied in HF clinical trials. [6][7][8][9][10] The importance of addressing the systemic underenrollment of some racial and ethnic groups has been previously highlighted 11 and remains an important directive of the US Food and Drug Administration (FDA) Safety and Innovation Act as well as the Inclusion Policy of the National Institutes of Health (NIH). 12 The Heart Failure Collaboratory, a consortium of stakeholders convened to enhance therapeutic development and delivery to patients with HF, 13 has been dedicated to improving recruitment strategies for diverse patient populations. This article is the direct result of virtual and in-person discussions among Collaboratory stakeholders with the goal of proposing strategies to improve enrollment in HF clinical trials of underrepresented racial and ethnic groups. We focus on the US perspective in the HF clinical trial landscape (with specific attention to enrollment of Black and Hispanic participants) and highlight US federal policies and initiatives to promote improved racial and ethnic representation. We recognize the need as well for improving enrollment of other populations of interest, including women, older adults, and people in rural areas of the United States [14][15][16][17] ; however, this call to action focuses on building sustainable pathways to improve future diverse participation with respect to race and ethnicity. Barriers in Underrepresented HF Trial EnrollmentMany racial and ethnic populations continue to experience socioeconomic deprivation, chronic discrimination, and stress that worsen health outcomes across the lifespan. [18][19][20][21] The ability and willingness of patients with HF to actively participate in clinical trials is intricately tied to social determinants of health, such as access to health care, education, income equality, and food security as well as cultural and community values. 22 This underrepresentation likely results from limited access both to clinical care and the current clinical IMPORTANCE Despite bearing a disproportionate burden of heart failure (HF), Black and Hispanic individuals have been poorly represented in HF clinical trials. Underrepresentation in clinical trials limits the generalizability of the findings to these populations and may even introduce uncertainties and hesitancy when translating trial data to the care of people from underrepresented groups. The Heart Failure Collaboratory, a consortium of stakeholders convened to enhance HF therapeutic development, has been dedicated to improving recruitment strategies for patients from diverse and historically underrepresented groups.OBSERVATIONS Despite federal policies from the US Food and Drug Administration and National Institutes of Health aimed at i...

show abstract

Section: Research Study Design and Site Selectionmentioning

confidence: 99%

“…It is important when collecting patient-reported outcomes that language-specific wording be used. For instance, validated HF-specific instruments such as the Kansas City Cardiomyopathy Questionnaire in a patient’s native language should be used when possible …”

Section: Introductionmentioning

confidence: 99%

Improving Enrollment of Underrepresented Racial and Ethnic Populations in Heart Failure Trials

et al. 2022

View full text Add to dashboard Cite

show abstract

“…A recent study reviewed all HRQoL outcome measures in CHF and found that the KCCQ and MLHF are the most specific and widely incorporated in clinical research [6]. Previous validation studies have compared the original KCCQ-23 with other HRQoL outcome measures, including the Short-Form-36, the MLHF, the EuroQol-5D, and the New York Heart Association (NYHA) classification [9][10][11][12][13]. However, there is no study so far that has compared the KCCQ-12 with other quality of life scales in patients with CHF, which makes the comparison impossible.…”

Section: Discussionmentioning

confidence: 99%

“…The KCCQ-12 has been translated into several languages, including Arabic, and has been tested on patients with CHF from diverse ethnic backgrounds [9][10][11][12][13]. However, no study has yet examined the use of the KCCQ-12 in Arabic-speaking patients with CHF with reduced ejection fraction.…”

Section: Introductionmentioning

confidence: 99%

Reliability and Validity of Kansas City Cardiomyopathy Questionnaire in Arabic Patients with Chronic Heart Failure

Albarrati,

Altimani,

Almogbel

et al. 2023

Medicina

View full text Add to dashboard Cite

Background: The Kansas City Cardiomyopathy Questionnaire (KCCQ) is the most specific and widely used questionnaire for assessing health-related quality of life (HRQoL) in chronic heart failure (CHF). This study aimed to examine reliability and validity of the KCCQ in Arabic patients with CHF. Material and Methods: Patients with CHF filled out the Arabic versions of the Minnesota Living with Heart Failure (MLHF) and KCCQ questionnaire, and performed a six-minute walk test (6MWT) on their first visit. On the return, the patients filled out the KCCQ along with the global rating of change (GRC) scale. Internal consistency, test–retest reliability, and construct validity were examined. Results: A total of 101 Arabic patients with CHF, with a mean (SD) age of 55 (11) years old, completed the study. The Cronbach’s alpha was 0.97, and the ICC2,1 = 0.95 (95%CI: 0.92 to 0.97, p < 0.001). The Arabic version of KCCQ was correlated with the MLHF (r = −0.57, p = 0.01) and with the 6MWT (r = 0.70, p < 0.001). Conclusions: The Arabic version of KCCQ is a reliable and valid measure of HRQoL, which could be utilized in routine clinical practice for Arabic-speaking patients with CHF.

show abstract

Assessment of patient-reported outcomes measures in heart failure: a systematic review

Mendes,

dos Santos,

Sousa-Pinto

2024

Heart Fail Rev

View full text Add to dashboard Cite

Psychometric properties of the Japanese version of the Kansas City Cardiomyopathy Questionnaire in Japanese patients with chronic heart failure

Cited by 3 publications

References 37 publications

Improving Enrollment of Underrepresented Racial and Ethnic Populations in Heart Failure Trials

Improving Enrollment of Underrepresented Racial and Ethnic Populations in Heart Failure Trials

Reliability and Validity of Kansas City Cardiomyopathy Questionnaire in Arabic Patients with Chronic Heart Failure

Assessment of patient-reported outcomes measures in heart failure: a systematic review

Contact Info

Product

Resources

About